Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp123 | Endocrine Tumours | ECE2017

Outcome of patients with adrenocortical cancer after discontinuation of adjuvant mitotane therapy

Terzolo Massimo , Basile Vittoria , Megerle Felix , Hermann Wiebke , Cicciarella Federica , Libe Rossella , Baudin Eric , Haak Harm , Mannelli Massimo , Boscaro Marco , Quinkler Marcus , Bourdeau Isabelle , Perotti Paola , Hahner Stefanie , Beuschlein Felix , Fassnacht Martin

Background: Adjuvant mitotane therapy is frequently used in Europe following surgery for adrenocortical carcinoma (ACC). Management of adjuvant mitotane is mainly empirical and a major open question is the optimal duration of therapy, because no study has ever addressed this issue.Objective: We aimed to assess the outcome of ACC patients who were treated with adjuvant mitotane for at least one year following surgery and then discontinued therapy for othe...